| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Qiagen N.V.$41.51
-0.48 (-1.14%)
D 25Pipeline Score Tools & Services · Commercial
Market Cap
7.25 B
EPS
1.95
P/E Ratio
18.17 $
Value Trade
117.08 M
5.74 %
Week
-12.51 %
1 Month
-27.42 %
3 Month
-27.08 %
6 Month
-35.02 %
5 Year
1,504.93 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
3.56 M
52 Week Range
32.53 - 57.82
% held by Insiders
0.6 %
% held by Institutions
78.51 %
Enterprise Value
8.25 B
Total Shares
222.20 M
Short %
2.99 %
Float Shares
221.31 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Qiagen N.V.
384Total events
7Upcoming
109Tier-1 (high impact)
2005 – 2028Coverage
Upcoming catalysts 7
Dec 2027
T2Product Launch
First customer application of AI-powered risk stratification tool based on QuantiFERON
2028
T1NDA Submission
Planned U.S. and European submissions of three panels (blood culture, cUTI, pneumonia) by 2028
TBD
T2Product Launch
Key projects in development for QIAstat-Dx involve new panels for complicated urinary tract infections, pneumonia and companion diagnostics
Event history 377
Jun 2026
Jun 2026
◆Product LaunchPost-Market
QIAsymphony Connect full IVDR commercialization targeted for mid-2026
May 20, 2026
▲Product LaunchPost-Market
Global launch of QIA Agent, an AI-powered digital assistant for researchers
May 7, 2026
▲Partnership / LicenseCorporate
Automation partnership with Inpeco for QuantiFERON IGRA testing
May 7, 2026
◆Oral PresentationQuantiFERONPresentation
QuantiFERON Spotlight Session on strategic priorities and latest update
latent TBsource ↗
May 6, 2026
Apr 17, 2026
Drug Pipeline Intelligence
D25
Pipeline Score $110M
Pipeline ValueValuation Signal
1
Drugs Scored0.0x
rNPV / MCap Top 24%
Small Cap (rank 694 of 912)
Percentile RankQiagen N.V. faces pipeline headwinds (25/100), with $177M risk-adjusted pipeline value, led by NEU-411 in Parkinson Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NEU-411 Small molecule | Parkinson Disease | Phase 2 | NCT06680830 | 21% | $177M | RECRUITING | 150 | FAST | A (81) | Sep 1, 2027 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
QGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QGENQIAGEN erweitert sein QIAcuity-Portfolio für Genexpressionsanalysen und treibt so den Einsatz der digitalen PCR in Forschung und Biopharma weiter voran
QIAGEN is expanding its QIAcuity portfolio for gene expression analysis, enhancing the application of digital PCR in research and biopharma. This move indicates a strategic effort to advance technological capabilities in the field. The expansion aims to meet growing demands in gene expression studies.
Read more →QGENQIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
QIAGEN has announced an expansion of its QIAcuity gene expression portfolio. This initiative is designed to enhance the adoption of digital PCR technologies within the research and biopharma industries. The company's efforts reflect a commitment to advancing molecular diagnostics and supporting scientific innovation.
Read more →QGENQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
QIAGEN is involved in supporting research and surveillance efforts related to the Bundibugyo Ebolavirus outbreak. The company's contributions aim to enhance the understanding and management of this infectious disease. Further details on specific initiatives or collaborations were not provided in the article.
Read more →QGENQIAGEN unterstützt Forschungs- und Überwachungsmaßnahmen zum Ausbruch des Bundibugyo-Ebolavirus
QIAGEN is involved in research and monitoring efforts related to the Bundibugyo Ebola virus outbreak. The company's support aims to enhance understanding and response to the outbreak. Further details on specific initiatives or collaborations were not provided in the article.
Read more →QGENQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
QIAGEN has launched the QIA Agent, an innovative tool designed to provide AI-driven scientific guidance throughout its Sample to Insight workflows. This new product aims to enhance the efficiency and effectiveness of scientific research by integrating advanced AI capabilities. The launch reflects QIAGEN's commitment to leveraging technology for improved scientific outcomes.
Read more →QGENQIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
QIAGEN is set to enhance its drug discovery efforts by utilizing AI-driven technologies, particularly graph-based AI and curated bioinformatics knowledge in collaboration with NVIDIA. This initiative aims to streamline and improve the efficiency of drug discovery processes. The partnership is expected to leverage advanced computational methods to analyze biological data effectively.
Read more →QGENQIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Qiagen N.V. on behalf of its stockholders regarding potential violations of federal securities laws. The investigation follows a significant drop in Qiagen's stock price, which fell approximately 11% after the company reported a 1% decline in net sales and a 5% decline in sales of its QuantiFERON product for the first quarter of 2026. Investors who have suffered losses are encouraged to contact the law firm for further legal options related to their investments.
Read more →QGENQIAGEN plant die Ernennung von Dr. Metin Colpan zum Ehrenvorsitzenden des Aufsichtsrats, setzt die Neuausrichtung der Aufsichtsratsstruktur fort und schlägt höhere Kapitalrückzahlungen auf der Hauptversammlung 2026 vor
QIAGEN has appointed Dr. Metin Colpan as the honorary chairman of the supervisory board. This decision continues the restructuring of the board's structure. Additionally, the company proposes higher capital returns at the 2026 general meeting.
Read more →QGENQIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
QIAGEN has announced the appointment of Dr. Metin Colpan as the Honorary Chairman of the Supervisory Board. This decision is part of the company's ongoing governance renewal efforts. Additionally, QIAGEN plans to propose increased returns at the upcoming 2026 Annual General Meeting.
Read more →QGENQIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
QIAGEN plans to enhance its QuantiFERON latent TB testing with a fully automated Sample to Insight workflow and an AI-enabled risk stratification tool. Set for launch in late 2027, these innovations aim to improve testing efficiency and scalability in response to increasing demand. The partnership with Inpeco will facilitate total laboratory automation, enhancing throughput and reducing manual intervention.
Read more →QGENQIAGEN plant Einführung eines neuen, vollautomatisierten Sample-to-Insight-Workflows und eines KI-gestützten Tools zur Risikostratifizierung als Weiterentwicklung seines QuantiFERON-Tests zum Nachweis latenter Tuberkulose
QIAGEN announced plans to enhance its QuantiFERON test for latent tuberculosis (TB) with a new automated Sample-to-Insight workflow and an AI-based risk stratification tool. These innovations aim to support high-throughput laboratories in meeting the increasing demand for latent TB screenings. The automated workflow is set to launch by the end of 2027, targeting users of Diasorin's LIAISON systems.
Read more →QGENQIAGEN reports full results for Q1 2026 Q1 2026 results in line with pre-announcement Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least
QIAGEN's Q1 2026 results indicate a 2% increase in net sales, reaching $492 million, though sales at constant exchange rates fell by 1%. Adjusted diluted earnings per share matched previous forecasts at $0.54, supported by growth in sample technologies and QIAcuity. However, the company faces challenges, notably a decline in QuantiFERON sales linked to decreased demand for immigration testing. QIAGEN has updated its full-year outlook, now anticipating a more modest growth rate of 1-2% due to ongoing demand uncertainties in the U.S. Life Sciences sector.
Read more →QGENQIAGEN Reports Full Results for Q1 2026
QIAGEN's report for Q1 2026 is mentioned, but the article provides minimal information. It lacks detailed insights into the company's financial performance or operational highlights. The content is insufficient for a comprehensive analysis of QIAGEN's current status.
Read more →QGENQIAGEN meldet vollständige Ergebnisse für das erste Quartal 2026
QIAGEN has reported complete results for the first quarter of 2026. However, the article does not provide specific financial data or insights regarding the company's performance during this period. Further details on revenue, product performance, or market conditions are not included.
Read more →QGENQiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims from investors of Qiagen N.V. following disappointing financial results announced on April 27, 2026. Qiagen revealed a decline of about 1% in net sales and a significant 5% drop in QuantiFERON product sales, attributed partially to reduced demand in immigration testing. Consequently, the company lowered its 2026 sales growth outlook, leading to a 10% stock price decline and prompting calls for accountability under federal securities laws.
Read more →QGEN▼ -10.7%on this newsshared move
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook
QIAGEN reported preliminary Q1 2026 results with adjusted EPS meeting expectations at $0.54. While overall sales increased by 2%, QuantiFERON sales fell due to decreased immigration testing demand. The company has revised its full-year sales growth outlook down to 1-2% from at least 5%. QIAGEN anticipates stronger growth in the latter half of 2026.
Read more →QGENQIAGEN meldet vorläufige Ergebnisse für das erste Quartal 2026: Bereinigter Gewinn je Aktie entspricht bei gemischten Umsatztrends den Erwartungen; Jahresprognose 2026 aktualisiert
QIAGEN has reported preliminary results for Q1 2026, indicating that the adjusted earnings per share meet expectations amidst mixed revenue trends. The company has also updated its annual forecast for 2026. Further details on the performance and outlook were not disclosed in the article.
Read more →QGENQIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
QIAGEN N.V. announced its participation in the AACR Annual Meeting 2026, where it will showcase its Sample to Insight solutions for oncology applications. The focus will be on addressing challenges in cancer research, such as fragmented workflows and complex multi-omics data. The portfolio aims to standardize processes from sample preparation to data interpretation, enhancing consistency and insights in molecular diagnostics.
Read more →QGENQIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
QIAGEN has launched the QIAstat-Dx BCID GPF Plus AMR Panel, a new rapid testing solution for bloodstream infections. This CE-IVDR-certified panel can identify multiple pathogens and antimicrobial resistance markers from blood cultures in approximately one hour. The launch coincides with the ESCMID Global 2026 Congress, showcasing QIAGEN's commitment to advancing infectious disease diagnostics.
Read more →QGENQiagen Announces Form 20-F Annual Report Filing for 2025 Results
QIAGEN N.V. has filed its Form 20-F annual report for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible on QIAGEN's website. Shareholders can request printed copies at no cost.
Read more →QGENQIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
QIAGEN announced new data supporting the QuantiFERON-TB Gold Plus test's effectiveness in detecting tuberculosis, particularly in high-risk populations. A recent study showed that QFT-Plus reduced the risk of progression to active TB by 41% compared to traditional methods. The announcement coincides with World TB Day, emphasizing the need for improved TB detection and prevention.
Read more →QGENQIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
QIAGEN reported a 4% increase in Q4 2025 net sales, reaching $540 million, surpassing expectations despite challenges like the U.S. government shutdown. The company's growth pillars showed a 7% increase in constant exchange rates. For 2026, QIAGEN anticipates at least 5% sales growth, driven by these growth pillars and successful acquisitions. Adjusted diluted EPS also exceeded forecasts.
Read more →QGENQIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
QIAGEN showcased its QIAsprint Connect high-throughput automation system at SLAS 2026 in Boston. This innovative system is designed for efficient sample processing in research labs, supporting up to 192 samples per run. The launch emphasizes QIAGEN's commitment to sustainability and automation, alongside other platforms like QIAsymphony Connect and QIAmini.
Read more →QGENQIAGEN exceeds Q4 2025 outlook driven by growth pillars Q4 2025 Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)) diluted EPS of $0.49 and adjusted diluted EPS of $0.62 N
QIAGEN reported a strong performance for Q4 2025, exceeding expectations with net sales of $540 million and adjusted diluted EPS of $0.62. Despite facing challenges such as the U.S. government shutdown and discontinued products, the company's growth pillars contributed notably to its financial results, reflecting robust execution and market adaptability. The company anticipates a continued increase in sales for 2026, supported by ongoing investments and strategic acquisitions.
Read more →QGEN▲ +16.6%on this news
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
QIAGEN N.V. has announced the release of its financial results for the fourth quarter of 2025, scheduled for February 4. A conference call will follow on February 5, allowing stakeholders to discuss the results. The company continues to emphasize its role in providing Sample to Insight solutions in the life sciences and molecular diagnostics sectors.
Read more →QGENQIAGEN announces details for completion of synthetic share repurchase of up to approximately $500 million Return of approximately $500 million - maximum approved by shareholders - set to be completed on
QIAGEN announced details of a synthetic share repurchase plan to return approximately $500 million to shareholders, scheduled for completion on January 7, 2026. This initiative, combining a direct capital repayment and a reverse stock split, aims to enhance earnings per share. The company has already returned around $650 million to shareholders since 2024 and is set to exceed its commitment of returning at least $1 billion by the end of 2028. Shareholder approval for this plan was nearly unanimous during the Annual General Meeting in June 2025.
Read more →QGENQIAGEN exceeds Q3 2025 outlook, raises FY 2025 adj. EPS target, announces Parse acquisition and $500 million share repurchase Q3 2025 results Net sales of $533 million (+6% at actual rates) diluted EPS $0.6
QIAGEN announced strong Q3 2025 results, exceeding sales and adjusted EPS expectations with net sales of $533 million and adjusted diluted EPS of $0.61. The company reaffirmed its full-year outlook, raising its adjusted EPS target to about $2.38. Notably, QIAGEN is set to acquire Parse Biosciences to enhance its Sample technologies offering, targeting growth in the single-cell market. Additionally, they approved a $500 million share repurchase plan to enhance shareholder value.
Read more →QGENQiagen NV (QIA): 2025 Product Pipeline and Strategy Analysis Report
The report titled 'Qiagen NV (QIA) - Product Pipeline Analysis, 2025 Update' provides an in-depth analysis of Qiagen's product pipeline and strategies for market competitiveness. It offers detailed information on pipeline products, including development stages, regulatory paths, and ongoing clinical trials. Key competitors and market trends are also reviewed to aid in the formulation of effective business strategies. This report serves as a vital resource for stakeholders looking to understand and navigate the medical devices landscape as of 2025.
Read more →QGENNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD
QIAGEN N.V. has announced a non-US offering of senior, unsecured net share settled convertible bonds worth USD 750 million. The bonds are due in 2032 and will be issued in denominations of USD 200,000. Interest rates will range from 1.75% to 2.25%, with proceeds earmarked for general corporate purposes, including refinancing existing debt. The offering is aimed at non-U.S. institutional investors only and is not available for public offering in various jurisdictions due to legal restrictions.
Read more →QGENQIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability Q2 2025 results Net sales of $534 million (+7% actual rates) adjusted diluted EPS of $0.60 Net sales +6% CER (constant exchang
QIAGEN reported strong results for Q2 2025, achieving net sales of $534 million, which is a 7% increase compared to Q2 2024. The company's adjusted diluted earnings per share reached $0.60, exceeding prior estimates. Key drivers of growth included double-digit increases in Diagnostic solutions, particularly from products like QIAstat-Dx and QuantiFERON. Based on its robust performance, QIAGEN also raised its full-year net sales outlook and reaffirmed its earnings targets for 2025.
Read more →QGENQIAGEN announces election of Stephen Rusckowski as Chairman of Supervisory Board Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM former Chairman Lawrence A. Rosen did not stand for re-electio
QIAGEN N.V. has announced the election of Stephen Rusckowski as the new Chairman of the Supervisory Board following the Annual General Meeting on June 26, 2025. He succeeds Lawrence A. Rosen, who served for 12 years and chose not to seek re-election. Shareholders approved major resolutions, including QIAGEN's inaugural annual cash dividend of $0.25 per share, totaling approximately $54 million, and a new share repurchase authorization of up to $500 million, affirming the company's solid financial standing and commitment to returning capital to shareholders.
Read more →QGENQIAGEN delivers solid Q1 2025 results exceeding outlook will seek shareholder approval to initiate a dividend and new $500 mn repurchase Q1 2025 results confirm preliminary announcement Net sales of $483 mi
QIAGEN reported solid Q1 2025 results with net sales reaching $483 million, a 7% increase at constant exchange rates. The company exceeded its earnings expectations, posting an adjusted diluted EPS of $0.56 against a prior outlook of at least $0.50. QIAGEN also plans to propose a dividend and a $500 million share repurchase, reflecting its commitment to enhancing shareholder value. The fiscal outlook for 2025 remains optimistic with a reaffirmed sales growth target of approximately 4% and an adjusted EPS target of about $2.35.
Read more →QGEN▲ +5.4%on this news
QIAGEN delivers strong preliminary Q1 2025 results exceeding outlook and raises full-year 2025 adjusted EPS outlook Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both ab
QIAGEN N.V. recently reported preliminary results for Q1 2025 that have surpassed expectations, with net sales increasing by approximately 7% at constant exchange rates, achieving around $483 million. The company's adjusted diluted EPS is projected to be at least $0.55, higher than the previously anticipated $0.50. Due to this robust performance, QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook from $2.28 to about $2.35. The company is optimistic about continuing to exceed its adjusted operating income margin goals.
Read more →QGENQIAGEN delivers solid Q4 2024 growth ahead of outlook Q4 2024 Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth) diluted EPS of $0.39 and adjusted diluted EPS of $0.
QIAGEN reported solid Q4 2024 results, achieving net sales of $521 million and adjusted diluted EPS of $0.61, both exceeding expectations. The company's diagnostic solutions saw double-digit growth, particularly in QuantiFERON and QIAstat-Dx. However, diluted EPS was down compared to the previous year, and overall operating income saw a significant decline amid pressures on instrument sales. Despite these challenges, QIAGEN remains optimistic about continued growth into 2025, projecting a 4% increase in net sales and a focus on improving operating margins.
Read more →QGENQIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million Capital return to be conducted through synthetic share repurchase - combines a fast direct capital repayment to sh
QIAGEN N.V. announced a synthetic share repurchase program aimed at returning approximately $300 million to shareholders. This initiative combines a direct capital repayment with a reverse stock split, which is expected to enhance earnings per share. The repurchase is part of a broader commitment to return at least $1 billion to shareholders by 2028. The program follows a previous return of $300 million completed in early 2024, reflecting QIAGEN's ongoing strategy to deliver value to its investors.
Read more →QGENQIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase Capital return to be conducted through synthetic share repurchase - combines a fast direct capital repayment to shareholder
QIAGEN N.V. has announced plans to return approximately $300 million to shareholders through a synthetic share repurchase, set for completion in late January 2025. This initiative combines direct capital repayment with a reverse stock split to enhance earnings per share. The decision follows an earlier $300 million return in early 2024, contributing to a broader commitment to return at least $1 billion by the end of 2028. CEO Thierry Bernard emphasized the importance of this strategy in delivering value to shareholders.
Read more →QGENQIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis
QIAGEN has launched two innovative tools for customizing digital PCR assays and NGS panels aimed at microbial analysis. These tools enhance the capabilities of researchers in detecting bacterial, fungal, and viral targets. The new offerings build on existing digital PCR assays and are designed to improve accuracy and precision in various applications, including wastewater testing and food production.
Read more →QGENQIAGEN collaborates with McGill University to advance microbiome research
QIAGEN has announced a three-year collaboration with McGill University to advance microbiome research. This partnership will focus on DNA extraction and anaerobic culturing protocols, enhancing QIAGEN's presence in the $1.8 billion microbiome market. The collaboration aims to support scientific research and training, ultimately improving health insights derived from microbiome studies.
Read more →QGENQIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook
QIAGEN N.V. reported a 5% increase in net sales for Q3 2024, reaching $502 million, surpassing expectations. The adjusted diluted EPS rose to $0.57, with an increased full-year outlook for adjusted EPS to at least $2.19. The company continues to benefit from a strong portfolio and operational efficiencies, reaffirming its commitment to profitable growth.
Read more →QGENQIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook Q3 2024 Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER) diluted EPS of $0.
QIAGEN reported robust Q3 2024 results, with net sales reaching $502 million, exceeding forecasts. The company increased its full-year adjusted earnings per share (EPS) outlook to a minimum of $2.19, reflecting strong growth in its Diagnostic solutions segment. Notably, free cash flow soared by 73% in the first nine months. Despite some challenges including a decline in instrument sales, the overall performance indicates resilience amid a tough macro environment.
Read more →QGENQIAGEN erhält FDA-Zulassung für QIAstat-Dx Meningitis/ Enzephalitis-Panel zur Unterstützung der Notfalldiagnostik
QIAGEN has received FDA approval for its QIAstat-Dx Meningitis/Encephalitis Panel, marking the fourth such approval in 2024. This panel provides rapid diagnostic results, significantly improving the speed of treatment for serious conditions like meningitis and encephalitis. The test can deliver results in about one hour, addressing the urgent need for timely medical interventions.
Read more →QGENQIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics
QIAGEN has received FDA clearance for its QIAstat-Dx Meningitis/Encephalitis Panel, enhancing emergency diagnostics for these critical conditions. This panel is the fourth QIAstat-Dx test to gain regulatory approval in 2024, allowing healthcare providers to obtain results in approximately one hour, significantly faster than traditional methods. The test analyzes multiple pathogens simultaneously, improving treatment decisions for clinicians.
Read more →QGENQIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen
QIAGEN has received FDA approval for its QIAstat-Dx Respiratory Panel Mini, designed to aid in diagnosing upper respiratory infections in outpatient settings. This panel tests for five common viral pathogens, providing rapid results in about an hour. The approval marks the third test in 2024 for use with QIAstat-Dx systems, enhancing clinical decision-making and patient care.
Read more →QGENQIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment
QIAGEN has received FDA clearance for its QIAstat-Dx Respiratory Panel Mini, aimed at diagnosing upper respiratory infections in outpatient settings. This test covers five common viral pathogens and delivers results in about an hour. It complements the previously cleared QIAstat-Dx Respiratory Panel Plus, enhancing diagnostic options for clinicians. The new panel is expected to improve patient care and reduce unnecessary antibiotic use.
Read more →QGENQIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications
QIAGEN has announced significant updates to its liquid biopsy technology portfolio, aimed at improving non-invasive applications in oncology, prenatal care, and organ transplantation. These enhancements include new automated kits and updates to existing platforms designed to increase sample processing capabilities and efficiency. The upgraded EZ1&2 ccfDNA Kit can now handle larger sample volumes, crucial for detecting low-frequency mutations. Additionally, the new kits support a range of molecular detection technologies, offering comprehensive solutions for research and diagnostics laboratories.
Read more →QGENQIAGEN N.V. to release results for Q3 2024 and hold webcast
QIAGEN N.V. has announced that it will release its financial results for the third quarter of 2024 on November 6, shortly after the end of trading. A conference call will take place the following day, November 7, to discuss the results with analysts and investors. The company provides innovative solutions for molecular insights, catering to over 500,000 customers globally across various sectors, including healthcare and life sciences.
Read more →QGENQIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology
QIAGEN has launched the QIAcuityDx Digital PCR System aimed at enhancing clinical diagnostics, particularly in oncology. The system offers precise quantitation of target DNA and RNA, facilitating less invasive liquid biopsies for cancer monitoring. This launch signifies QIAGEN's commitment to advancing digital PCR technology and improving workflows within clinical laboratories. Additionally, QIAGEN plans to expand its assay offerings on the platform and has already initiated collaborations with pharmaceutical partners for developing companion diagnostics.
Read more →QGENQIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays
QIAGEN has announced that its QIAstat-Dx syndromic testing systems and assays have received European IVDR certification. This includes the QIAstat-Dx Analyzer, QIAstat-Dx Rise, and various panels for gastrointestinal and respiratory illness detection. The certification reflects QIAGEN's adherence to the rigorous safety and quality standards set by the EU's new In-Vitro Diagnostic Medical Devices Regulation. Additionally, the QIAstat-Dx system offers rapid multiplex testing capabilities, aimed at enhancing patient care by delivering quick and accurate results.
Read more →QGENQIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database
QIAGEN has partnered with Bode Technology to enhance the GEDmatch PRO forensic genetic genealogy database. This multi-year agreement aims to improve law enforcement's ability to solve cold cases through advanced DNA analysis technologies. Bode will manage all commercial operations for GEDmatch PRO globally, while QIAGEN will focus on developing new features. The partnership reinforces the commitment to data security and user privacy, ensuring that case data remains confidential.
Read more →QGENQIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform
QIAGEN has announced the launch of 100 new assays for its QIAcuity digital PCR platform, significantly expanding its capabilities for cancer research, genetic disorders, and infectious disease monitoring. This brings the total number of new assays launched this year to over 130, surpassing their 2024 targets. The QIAcuity platform is increasingly popular, with over 2,000 installations and applications in various fields including diagnostics and biopharma. Future developments will focus on clinical testing and companion diagnostics, enhancing the platform's applicability in healthcare.
Read more →QGENQIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs
QIAGEN has expanded its strategic partnership with Bio-Manguinhos/Fiocruz to improve malaria and dengue detection capabilities in Brazil. This partnership, which began in 2009, will now include a new PCR-based screening platform for detecting malaria in blood donations. Additionally, it enhances public health initiatives by supporting dengue epidemiological surveillance with tailored molecular kits. The initiative aims to increase transfusion safety and health surveillance across various regions of Brazil.
Read more →QGENThe Bonds are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ( EEA ) or Unit
QIAGEN N.V. announced the final terms of its new senior unsecured net share settled convertible bonds totaling $500 million. The initial conversion price for the bonds is set at approximately $64.01 per share, reflecting a 44% premium. The company plans to use the proceeds for general corporate purposes, including refinancing existing debt. However, it has mandated that these bonds cannot be offered to retail investors in the EEA or the UK, highlighting specific legal restrictions on its distribution.
Read more →QGENQIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer’s disease
QIAGEN has partnered with Eli Lilly to develop a QIAstat-Dx in-vitro diagnostic panel for detecting APOE genotypes associated with Alzheimer's disease. This represents the first commercial IVD for such genotyping. The collaboration aims to enhance diagnostic accuracy and improve treatment strategies for Alzheimer's patients. The panel will be integrated with QIAGEN's existing multiplex testing technology, which is already established in infectious disease diagnostics.
Read more →QGENQIAGEN N.V. announces conversion price of new net share settled convertible bonds
QIAGEN N.V. announced the details of new senior, unsecured convertible bonds totaling $500 million, with a conversion price set at $64.0129 per share, reflecting a 44.0% premium over its reference share price. The bonds will mature in 2031 and are expected to settle on September 10, 2024. QIAGEN plans to utilize the proceeds primarily for general corporate purposes, such as refinancing existing debt. The bonds will be available for trading on the Frankfurt Stock Exchange post-settlement.
Read more →QGENQIAGEN N.V. announces successful placement of new net share settled convertible bonds
QIAGEN N.V. has announced the successful placement of new senior unsecured convertible bonds worth $500 million, which can be partially converted into ordinary shares. The bonds, set to mature in 2031, will be issued at par with a coupon rate of 2.500% per annum, payable semi-annually. The initial conversion price will reflect a 44% premium over the reference share price, which will be determined at market close on September 3, 2024. A lock-up period will prevent QIAGEN from selling similar securities for 90 days following the settlement date.
Read more →QGENQIAGEN N.V. launches non-US offering of net share settled convertible bonds
QIAGEN N.V. has announced the launch of a non-US offering of senior unsecured net share settled convertible bonds, aiming to raise $450 million. The bonds will mature in 2031 and are set to be issued at par with a coupon rate between 2.125% and 2.625%. Approximately 6.9 million shares will underlie the bonds, representing 3.1% of QIAGEN's current share capital. The proceeds will be used for corporate purposes, including refinancing existing debts, with settlement expected on September 10, 2024.
Read more →QGENQIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases
QIAGEN announced an expansion of its collaboration with AstraZeneca to develop companion diagnostics for chronic diseases using the QIAstat-Dx platform. This agreement will allow the development of a genotyping assay that enables faster decision-making for patients undergoing treatment with AstraZeneca's genomically targeted medicines. QIAGEN emphasizes its expertise in companion diagnostics and aims to utilize the unique capabilities of the QIAstat-Dx system for clinical needs. The partnership highlights QIAGEN's commitment to advancing precision medicine through innovative molecular diagnostic solutions.
Read more →QGENNOTICE OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of Shareholders (the Annual General Meeting ) of QIAGEN N.V., a public limited liability company organized and e
QIAGEN N.V. has officially announced its Annual General Meeting (AGM) scheduled for June 21, 2024, in Venlo, Netherlands. Various agenda items will be addressed including the adoption of annual accounts for 2023, advisory votes on the remuneration report, and the reappointments of Supervisory and Managing Directors. The meeting will also involve voting on key corporate governance items and financial policies, including capital repayment methods. Shareholders can participate in the meeting remotely via a live webcast.
Read more →QGENQIAGEN delivers solid performance and exceeds outlook for Q2 2024 Q2 2024 Net sales of $496 million (+0% actual rates, +1% constant exchange rates, CER) net loss per share of $0.83 but adjusted diluted EPS
QIAGEN reported a solid performance for Q2 2024, achieving net sales of $496 million, which exceeded their outlook. The company also reported an adjusted diluted EPS of $0.55, surpassing the expected $0.52. Despite a net loss per share of $0.83 primarily due to restructuring charges related to the NeuMoDx system, QIAGEN updated its FY 2024 outlook positively. Free cash flow increased by 56%, highlighting robust financial health and performance improvements in targeted business areas.
Read more →QGENQIAGEN delivers solid performance and exceeds outlook for Q2 2024
QIAGEN N.V. reported stable net sales of $496 million for Q2 2024, slightly surpassing expectations at constant exchange rates. The company's adjusted operating income margin improved to 28.4%, attributed to efficiency gains. QIAGEN has updated its full-year outlook, projecting at least $1.985 billion in net sales, which factors in adjustments from the NeuMoDx system phase-out. The CEO expressed confidence in maintaining strong growth in core business operations throughout the remainder of 2024.
Read more →QGENQIAGEN to enhance the identification of human remains of Indigenous people and African Americans
QIAGEN has partnered with the Snow Molecular Anthropology Lab at the University of Montana to utilize DNA technologies in the identification of missing and murdered Indigenous people (MMIP) and African American remains. This collaboration will establish the first Indigenous-owned DNA database and aims to provide forensic services utilizing QIAGEN's advanced sequencing systems. The Snow Lab will work on identifying remains of 95 African Americans discovered during construction in Texas. This partnership highlights QIAGEN's commitment to supporting justice for affected families through innovative forensic solutions.
Read more →QGENQIAGEN N.V. to release results for Q2 2024 and hold webcast
QIAGEN N.V. has announced that it will release its results for the second quarter of 2024 on July 31. Following this, a conference call is scheduled for August 1, providing an opportunity for stakeholders to discuss the results. The company continues to emphasize its role as a leading provider of molecular insights with a robust customer base, reflecting its significant footprint in life sciences and molecular diagnostics.
Read more →QGENQIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children
QIAGEN has announced its positive response to new U.S. guidelines from the American Academy of Pediatrics (AAP) recommending the use of its QuantiFERON-TB Gold Plus test for screening latent tuberculosis in children of all ages. These guidelines aim to enhance TB detection, especially among at-risk children, and follow recent recommendations from the American College Health Association favoring modern testing methods. The expanded screening protocols are timely, given the rising cases of TB in the U.S., which have increased significantly post-COVID-19.
Read more →QGENQIAGEN announces 2028 strategy for solid profitable growth Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028
QIAGEN has outlined its strategy for 2024-2028 during its Capital Markets Day held in New York, focusing on achieving a compound annual sales growth rate of 7% and a 31% adjusted operating income margin by 2028. The company emphasizes disciplined capital allocation, high levels of R&D, and plans to return at least $1 billion to shareholders over the four-year period. Key growth initiatives include new product launches, particularly in digital PCR and diagnostics, as well as enhancements in operational efficiencies and digitization efforts. The strategy demonstrates QIAGEN's commitment to maintaining a competitive edge and profitability in the rapidly growing molecular diagnostics market.
Read more →QGENQIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs
QIAGEN has launched an upgraded version of its software QIAGEN Clinical Insight Interpret (QCI Interpret), designed to enhance clinical reporting turnaround times for NGS labs. This new version incorporates advanced AI capabilities that improve workflow scalability and facilitate the assessment of multiple variants simultaneously. With features like bulk variant assessment and enhanced user coordination, the tool is aimed at helping labs manage increased test volumes efficiently. In addition to these upgrades, QCI Interpret is now certified as a Class C Medical Device for European diagnostic use.
Read more →QGENQIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
QIAGEN has released its 2023 Sustainability Report, emphasizing its commitment to Environmental, Social, and Governance (ESG) principles. The report highlights a 15% reduction in emissions and ongoing efforts to reduce plastic usage and foster diversity within the workforce. Notably, QIAGEN is enhancing partnerships for expanded diagnostic access and has been recognized by rating agencies for its sustainability efforts. The company focuses on integrating ESG objectives within its operational framework, aiming for future improvements.
Read more →QGENQIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance
QIAGEN has launched 35 new digital PCR assays for microbial DNA detection, enhancing its QIAcuity platform. These assays target significant pathogens linked to tropical diseases, STIs, and UTIs, aiding in the research and surveillance of infectious diseases. The expansion reflects QIAGEN's aim to meet pressing research needs and improve detection accuracy. The company plans to showcase these innovations at the upcoming ASM Microbe conference in Atlanta, promising further expansions with more assays later in 2024.
Read more →QGENQIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development
QIAGEN has announced its decision to discontinue the NeuMoDx 96 and 288 Molecular Systems due to challenging market conditions post-pandemic. The company will support its customers during the transition while refocusing on other innovations within its portfolio. QIAGEN has reaffirmed its Q2 2024 outlook and raised its full-year adjusted diluted EPS prediction. A significant restructuring charge of around $400 million, including many non-cash items, is expected as a result of this decision.
Read more →QGENQIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe
QIAGEN has launched a new digital PCR Custom Assay Design Tool for copy number variation analysis on its QIAcuity platform, enhancing the GeneGlobe research platform. This tool provides researchers with options to design customized assays, addressing the rapid evolution of genetic research and the need for specific assays outside of pre-designed catalogs. Additionally, QIAGEN is working on user-friendly enhancements to further support assay development, aiming to improve scientific discovery and streamline research processes. The company also plans to expand its customization capabilities to microbial and somatic mutation assays later in 2024.
Read more →QGENQIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
QIAGEN has launched the QIAstat-Dx Gastrointestinal Panel 2 in the U.S., approved by the FDA for clinical use. This rapid test identifies up to 16 gastrointestinal pathogens within an hour, significantly enhancing diagnosis efficiency compared to traditional methods that take longer. The new panel aims to improve patient care by allowing healthcare providers to make timely, informed decisions and to mitigate unnecessary treatments and costs. QIAGEN continues to expand its portfolio of syndromic testing solutions, boosting its commitment to advancing molecular diagnostics.
Read more →QGENQIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
QIAGEN and Myriad Genetics have partnered to develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) using next-generation sequencing. This initiative aims to support research and improve companion diagnostics across various solid tumors, including ovarian cancer. The test will leverage QIAGEN’s technology and Myriad’s approved biomarkers, expecting to enhance decentralized testing capacities and expedite therapy decisions. The collaboration is anticipated to fulfill a growing demand for personalized cancer treatment solutions.
Read more →QGENQIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAGEN has launched the QIAseq Multimodal DNA/RNA Library Kit, which allows for efficient preparation of DNA and RNA libraries for next-generation sequencing (NGS). This kit streamlines workflows for multiomic studies, facilitating research in genomics and proteomics with a focus on diseases such as cancer. It is compatible with various sample types, including blood and cell-free DNA, and supports both DNA-only and RNA-only libraries. The introduction of this innovative kit is expected to enhance precision medicine and healthcare by providing a more efficient means of identifying potential biological markers and therapeutic targets.
Read more →QGENQIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
QIAGEN has announced that its updated clinical decision support platform, QIAGEN Clinical Insight Interpret, has received IVDR certification in the EU. This certification confirms the platform's compliance with regulatory standards for both oncology and hereditary applications. The updated version, which will be available in Europe later in 2024, enhances workflow efficiencies and turnaround times in molecular profiling. With extensive prior use and a robust analysis background, the platform is recognized for its reliability in clinical decision-making.
Read more →QGENQIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
QIAGEN has received FDA clearance for its QIAstat-Dx Respiratory Panel Plus, facilitating the diagnosis of upper respiratory infections by testing for 21 viral and bacterial targets. This test, which offers results within one hour and minimizes hands-on time, aims to improve patient care and reduce the burden on healthcare systems. The company is also working on expanding its product offerings in the U.S., including additional panels currently under FDA review.
Read more →QGENQIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
QIAGEN has entered into a cooperative research and development agreement with the FBI to create a groundbreaking digital PCR assay for forensic DNA quantification. The new assay aims to precisely measure nuclear and mitochondrial DNA concentrations, which is crucial for accurate forensic analysis in challenging samples. This collaboration marks a significant advancement in forensic science, leveraging QIAGEN's QIAcuity technology to enhance the reliability of evidence in criminal investigations. The initiative is expected to streamline operations and improve outcomes for forensic laboratories.
Read more →QGENQIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QIAGEN has launched QCI Secondary Analysis, a cloud-based software solution designed for high-throughput secondary analysis of next-generation sequencing (NGS) data. This new offering is aimed particularly at small- to mid-size molecular laboratories, facilitating greater access to comprehensive genomic testing. It integrates seamlessly with QIAGEN's existing products, providing an efficient workflow for testing in oncology and inherited diseases. The solution aims to simplify the analysis process while ensuring compliance with important data protection regulations.
Read more →QGENQIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance Q1 2024 Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER) diluted EPS of $0.36 a
QIAGEN N.V. reported its Q1 2024 results, with net sales of $459 million down 5% year-over-year. Despite this decline, their performance surpassed previous forecasts, particularly in the diagnostics segment where sales increased by 5%. The company reiterated its optimistic outlook for the full year, targeting at least $2 billion in net sales. QIAGEN's efforts in efficiency and strategic investments appear to support continued growth in specific product lines.
Read more →QGENQIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
QIAGEN N.V. has reported its Q1 2024 results, revealing a slight decline in net sales but a positive performance at constant exchange rates, which exceeded initial expectations. The company achieved an adjusted operating income margin of 25.7%, reflecting efficiency gains amid ongoing investments. Key areas of growth included significant sales increases in its QuantiFERON and QIAstat-Dx product lines. QIAGEN reaffirmed its full-year guidance, anticipating net sales of at least $2.0 billion and a rise in adjusted diluted EPS to a minimum of $2.10.
Read more →QGENQIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
QIAGEN has introduced the QIAseq xHYB Mycobacterium tuberculosis Panel, enhancing its tuberculosis portfolio to aid in real-time surveillance and combat antimicrobial resistance. This innovative tool allows for culture-free whole genome sequencing directly from samples, significantly reducing result wait times. The panel identifies all antimicrobial resistance-related genes, addressing the critical issue of drug-resistant tuberculosis. The product will be showcased at the ESCMID Global 2024 conference in Barcelona, reflecting QIAGEN's commitment to tackling global health challenges associated with tuberculosis.
Read more →QGENQIAGEN N.V. to release results for Q1 2024 and hold webcast
QIAGEN N.V. has announced plans to release its financial results for the first quarter of 2024 on April 29, 2024. A conference call will be held the following day, April 30, to discuss these results. Participants are encouraged to register in advance or join the audio webcast. QIAGEN is a leading provider of solutions for molecular insights from various samples, supporting numerous customers globally across multiple sectors.
Read more →QGENQIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
QIAGEN N.V. announced the launch of several new products aimed at enhancing cancer research, which will be showcased at the AACR Annual Meeting 2024. Notable innovations include the QIAcuity PanCancer kits designed to detect genetic mutations associated with cancer and a urine liquid biopsy setup for non-invasive DNA collection. The company will also highlight its QIAcuity IVD system intended for clinical applications in precision diagnostics. Overall, these advancements suggest a significant step forward for QIAGEN in providing tools for cancer detection and treatment monitoring.
Read more →QGENQIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
QIAGEN has launched the QIAstat-Dx Analyzer 2.0, featuring significant improvements such as the Remote Results Application for real-time access to diagnostic tests. This upgraded system allows healthcare professionals to view and confirm results from any location, enhancing collaboration across labs. The device utilizes advanced technology for fast and accurate diagnosis of multiple pathogens, supporting healthcare professionals worldwide in over 100 countries. These improvements aim to streamline workflows and ensure timely patient care through efficient diagnostic processes.
Read more →QGENQIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements
QIAGEN has partnered with the International Panel Physicians Association (IPPA) to promote awareness of tuberculosis (TB) screening requirements, focusing on the new Interferon Gamma Release Assay (IGRA). This collaboration follows updated CDC guidelines requiring IGRA testing for immigrants from high TB incidence countries. The partnership aims to ensure safer immigration processes and support the global fight against TB, particularly in identifying latent infections. QIAGEN is also hosting a global event for TB experts to discuss screening and preventive strategies in relation to World TB Day.
Read more →QGENQIAGEN announces Form 20-F annual report filing for 2023 results
QIAGEN N.V. has submitted its Form 20-F annual report to the U.S. Securities and Exchange Commission for the fiscal year ending December 31, 2023. This report includes audited consolidated financial statements and is accessible on QIAGEN's official website. The annual report will also be available in printed form to shareholders upon request, showcasing the company's commitment to transparency. The company continues to serve over 500,000 customers globally with its Sample to Insight solutions.
Read more →QGENQIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery
QIAGEN has launched a new generative AI-driven knowledge base called QIAGEN Biomedical KB-AI to enhance data-driven drug discovery. This resource offers over 640 million biomedical relationships, significantly more than its predecessor, and provides insights into gene-disease-drug connections. Designed for data scientists and bioinformaticians, the knowledge base helps identify drug targets and explore drug repurposing strategies. The integration of AI and human efforts is aimed at supporting researchers with comprehensive and reliable data for their projects.
Read more →QGENQIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification
QIAGEN has announced two achievements in sustainability with its eco-friendlier QIAwave nucleic-acid extraction kits receiving the ACT Environmental Impact Factor Label. The company also attained its first My Green Lab Platinum certification for its R&D lab in Germany. These accolades support QIAGEN's commitment to sustainability as it aims for net-zero greenhouse gas emissions by 2050 and further reductions in plastic usage. The company is recognized for its efforts by various independent rating agencies, showcasing its position as a leader in sustainable practices in the biopharma industry.
Read more →QGEN▲ +6.2%on this news
QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability
QIAGEN N.V. reported strong financial results for Q4 2023, with net sales of $503 million, surpassing the outlook of $500 million. The growth was primarily driven by an 8% sales increase in non-COVID products. Despite a decline in overall full-year sales by 8%, the company exceeded projected adjusted EPS. Looking ahead, QIAGEN expects at least $2.0 billion in sales for 2024, alongside anticipated challenges in larger-scale instrument sales and non-operating income.
Read more →QGENQIAGEN announces partnership with Penn State University to advance microbiome sciences
QIAGEN has entered into a partnership with Penn State University to advance microbiome sciences by creating a shared research and education facility. This collaboration aims to address challenges in microbiome research and includes an internship program for Penn State graduate students at QIAGEN's facilities. The partnership also focuses on fostering relationships within the microbiome research community and aims to develop new products based on direct customer feedback. Notably, the initiative supports projects that engage students in collecting scientific data related to microbiomes.
Read more →QGENQIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million Venlo, the Netherlands
QIAGEN N.V. announced a synthetic share repurchase plan to return up to $300 million to its shareholders, featuring a direct capital repayment and reverse stock split. The plan aims to reduce the issued shares by approximately 3%, consolidating every 25 shares into 24.25 shares. The capital repayment will be $1.28 per pre-split share, with trading of consolidated shares set to begin on January 30, 2024. QIAGEN advises shareholders to consult with their banks for further details on the consolidation and repayment process.
Read more →QGENQIAGEN N.V. to release results for Q4 2023 and hold webcast
QIAGEN N.V. has announced the release of its financial results for the fourth quarter and full year 2023, scheduled for February 6, 2024. A conference call will follow on February 7, where stakeholders can join via multiple connection options, including a callback service and an audio webcast. The company highlights its extensive presence and contributions within the molecular diagnostics and life sciences sectors, serving over 500,000 customers worldwide. This scheduled financial update reflects the company's commitment to transparency and engaging with its investor community.
Read more →QGENQIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems
QIAGEN has received FDA clearance for its NeuMoDx CT/NG Assay 2.0, expanding its offerings for the NeuMoDx 96 and 288 Molecular Systems in the U.S. The assay facilitates the rapid detection of both asymptomatic and symptomatic cases of Chlamydia trachomatis and Neisseria gonorrhoeae, which are prevalent sexually transmitted infections. This marks QIAGEN's first FDA approval for a NeuMoDx assay to be used on both systems, enhancing their diagnostic menu in the U.S. and possibly improving patient care through faster testing and results delivery.
Read more →QGENDocument QIAGEN announces plans to return approximately $300 million to shareholders Capital return to be conducted through synthetic share repurchase Return of up to $300 million - maximum approved by shareholders in 20
QIAGEN N.V. has announced a plan to return approximately $300 million to shareholders through a synthetic share repurchase. This strategy, approved by shareholders in June 2023, aims to enhance earnings per share (EPS) while efficiently returning cash to investors. The implementation is planned for late January 2024, combining direct capital repayment and a reverse stock split. QIAGEN's leadership expresses confidence in their growth prospects, citing a strong position and ongoing investments in profitable growth opportunities.
Read more →QGENQIAGEN announces plans to return approximately $300 million to shareholders
QIAGEN N.V. has announced a plan to return approximately $300 million to shareholders via a synthetic share repurchase. This approach, approved at the Annual General Meeting in June 2023, combines a direct capital repayment with a reverse stock split. CEO Thierry Bernard emphasized the company's strong start in 2024, while CFO Roland Sackers noted the value-enhancing structure of the repurchase. The process is scheduled to become effective on January 29, 2024.
Read more →QGENQIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business
QIAGEN has announced a strategic plan to significantly increase investments in its Digital Insights (QDI) bioinformatics business over the next five years. The investment aims to support the launch of at least five new products and enhance existing offerings in bioinformatics, particularly concerning Omics knowledge bases and artificial intelligence capabilities. QDI's strategy includes expanding its clinical secondary analysis solutions and strengthening its commercial presence and infrastructure to improve customer reach and services. The company cites robust sales growth and profitability in bioinformatics as key drivers for this investment initiative.
Read more →QGENQIAGEN expands business in Middle East with new regional headquarters and major projects
QIAGEN has announced a significant expansion into the Middle East, including the opening of a regional headquarters in Riyadh, Saudi Arabia, in 2024. This move follows a memorandum of understanding with Saudi Arabia's Ministry of Health aimed at improving public health and infection control. Additionally, QIAGEN will supply its QuantiFERON-TB Gold Plus tests to Oman for a nationwide tuberculosis screening program. These initiatives are part of QIAGEN's efforts to enhance regional healthcare and support public health initiatives like WHO programs for meningitis and cervical cancer screenings.
Read more →QGENQIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation
QIAGEN has expanded its sample technologies portfolio with the launch of the TissueLyser III and RNeasy PowerMax Soil Pro Kit. These products are designed to enhance the efficiency of sample processing and RNA isolation from difficult biological materials. The TissueLyser III offers high-throughput disruption capabilities while the RNeasy PowerMax Soil Pro Kit utilizes advanced Inhibitor Removal Technology to deliver high-purity RNA from challenging soil samples. This introduction reflects QIAGEN's commitment to improving research processes across various fields, including microbiome and biomedical research.
Read more →QGENQIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers
QIAGEN has launched three new digital PCR kits and a significant software update for its QIAcuity systems, aimed at enhancing applications in biopharma, food safety, and research. The new kits enable precise detection of contaminants and the quantification of RNA and DNA, while the software update offers features to streamline temperature regulation and dilution calculations in tests. This initiative reflects QIAGEN's commitment to advancing molecular testing technologies across various sectors.
Read more →QGENQIAGEN launches complete Sample to Insight workflow for microbiome research
QIAGEN has launched the Microbiome WGS SeqSets, a complete Sample to Insight workflow aimed at optimizing microbiome research. The workflow simplifies the steps of sample extraction and next-generation sequencing (NGS) library preparation, making it user-friendly for researchers lacking specialized expertise. This innovative solution enhances the efficiency of microbiome studies by improving DNA extraction and library preparation while providing intuitive bioinformatics analysis for researchers. The new SeqSets are part of QIAGEN's expanding microbiome solutions portfolio, designed for diverse applications including gut health and antibiotic resistance research.
Read more →QGENQIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System
QIAGEN and Element Biosciences have announced a strategic partnership to provide integrated next-generation sequencing (NGS) workflows for Element's AVITI System. This collaboration aims to enhance genomic research by offering versatile and cost-effective sequencing solutions. QIAGEN will supply validated NGS panels and bioinformatics software, streamlining genomic data analysis. Both companies plan to present their findings at the upcoming American Society of Human Genetics annual meeting.
Read more →QGENNOTICE OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS
QIAGEN N.V. has announced the date and agenda for its Annual General Meeting of Shareholders, scheduled for June 22, 2023, in Venlo, Netherlands. Key agenda items include the adoption of the Annual Accounts for 2022, advisory votes on the Remuneration Report, and the reappointment of Directors. Shareholders will have the opportunity to vote on several important items including the company's dividend policy and stock plan. Documentation related to the meeting will be available for shareholders ahead of the event.
Read more →QGENQIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER
QIAGEN reported a strong performance in Q3 2023, exceeding its sales outlook with net sales of $470 million at constant exchange rates. The growth was driven by a 5% increase in its non-COVID-19 product portfolio, while total sales saw a decline due to reduced COVID-19 related contributions compared to the previous year. Adjusted diluted earnings per share reached $0.50, surpassing the anticipated $0.48. The company affirmed its full-year 2023 sales outlook of at least $1.97 billion and aims for solid growth despite challenging market conditions.
Read more →QGENQIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
QIAGEN and Myriad Genetics have announced a master collaboration agreement to develop companion diagnostic tests for cancer. This partnership seeks to provide innovative diagnostic solutions that will be accessible to pharmaceutical companies and patients worldwide. QIAGEN will contribute its advanced technology and manufacturing capabilities, while Myriad will leverage its lab expertise and commercial infrastructure. The initial focus will be on utilizing next-generation sequencing workflows and exploring future projects related to measurable residual disease and homologous recombination deficiency.
Read more →QGENQIAGEN N.V. to release results for Q3 2023 and hold webcast
QIAGEN N.V. has announced the release date for its third quarter 2023 results, set for October 30, shortly after market close. A conference call for investors will follow on October 31, allowing stakeholders to engage with company representatives. These events reflect the company's commitment to transparency and open communication with its investors and clients. As a leading provider of molecular insights, QIAGEN continues to serve over 500,000 customers worldwide, underscoring its significant role in the diagnostics and life sciences sectors.
Read more →QGENQIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
QIAGEN has launched the QuantiFERON-EBV RUO assay, which aims to facilitate research into Epstein-Barr virus (EBV) infections and related diseases. This assay, designed for research use only, utilizes specific antigens to evaluate cell-mediated immune responses to EBV, which could provide insights into conditions such as post-transplant lymphoproliferative disorder and multiple sclerosis. The new assay expands QIAGEN's portfolio of tests that monitor immune responses associated with various diseases, potentially improving treatment monitoring and personalized care.
Read more →QGENQIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
QIAGEN has announced the enhancement of its QIAGEN Clinical Insight Interpret (QCI Interpret) software by integrating advanced AI capabilities for greater coverage of rare disease genes. This update improves the efficiency and accuracy of diagnostic processes, enabling labs to provide comprehensive clinical NGS reporting. Additionally, the software will allow users to focus on phenotype-specific literature, reducing the time needed for variant classification. The announcement follows significant adoption by institutions, enhancing its position as a leader in genomic diagnostics.
Read more →QGENQIAGEN’s QuantiFERON solutions recommended for use by kidney specialists in Tunisia
QIAGEN's QuantiFERON solutions have been recommended by the Tunisian Society of Nephrology for monitoring immune responses in kidney disease and transplant patients. This marks the first nationwide guidance of its type by a professional body in kidney medicine. The tests aim to identify risks for complications such as CMV disease and latent TB, allowing for tailored treatment strategies. Overall, this guidance is expected to enhance patient care and reduce healthcare costs in Tunisia.
Read more →QGENQIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report
QIAGEN has released its 2022 Sustainability Report, highlighting its commitment to Environmental, Social and Governance (ESG) initiatives. The report details significant progress, such as a 20% reduction in Scope 1 and 2 emissions and a 16.5% decrease in plastic usage. QIAGEN's emissions reduction targets have been validated by the Science Based Targets initiative, aiming for net-zero GHG emissions by 2050. The company has also worked on improving diversity and expanding access to healthcare solutions globally, significantly contributing to communities in low-resource countries.
Read more →QGENQIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits
QIAGEN has expanded its QIAwave product line with two new eco-friendlier nucleic acid extraction kits: the QIAwave RNeasy Plus Mini Kit and the QIAwave DNA/RNA Mini Kit. These new kits use significantly less plastic and cardboard while delivering the same high-quality performance as their conventional counterparts. With this launch, QIAGEN underscores its commitment to sustainability by reducing its environmental footprint in laboratory practices. The company has set a goal to achieve net-zero greenhouse gas emissions by 2050, reflecting its dedication to environmental stewardship.
Read more →QGENQIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook
QIAGEN reported higher than expected net sales for Q2 2023, achieving $497 million. This result is driven by a 9% sales increase in its non-COVID product range despite an overall 4% decline in sales compared to Q2 2022. The company has revised its full-year 2023 sales forecast down to at least $1.97 billion, largely due to decreased demand for COVID-19 tests. However, optimism is present with continued strong performance in consumables and growth expected beyond 2023.
Read more →QGENQIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT (avapritinib) in gastrointestinal stromal tumors
QIAGEN has announced FDA approval for its therascreen PDGFRA RGQ PCR kit, a companion diagnostic for identifying gastrointestinal stromal tumor patients eligible for treatment with AYVAKIT. This assay, developed in collaboration with Blueprint Medicines, is the first of its kind to receive FDA approval, targeting a specific mutation associated with GIST. This approval emphasizes QIAGEN's leadership in the field of companion diagnostics, adding to its portfolio of FDA-approved assays.
Read more →QGENQIAGEN N.V. to release results for Q2 2023 and hold webcast
QIAGEN N.V. is set to release its Q2 2023 results on August 8, 2023. This announcement is accompanied by a conference call scheduled for August 9, where stakeholders can join to discuss the results. The company emphasizes its role as a leading provider of Sample to Insight solutions in molecular diagnostics and life sciences, catering to over 500,000 customers globally.
Read more →QGENQIAGEN expands range of digital PCR kits and services for the biopharma industry
QIAGEN has announced the expansion of its digital PCR offerings aimed at the biopharma industry, particularly for cell and gene therapies. The company has partnered with Niba Labs to provide customized assay design services, enhancing their product offerings. Additionally, the new CGT Viral Vector Lysis Kit has been launched to improve the quantification of viral titers, facilitating drug development and quality control. These advancements address the evolving needs of biopharma developers working on next-generation therapies.
Read more →QGENQIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notes
QIAGEN N.V. has reiterated details regarding the mechanics for the settlement of its convertible notes due in 2023 and 2024. This notification follows prior communication to note holders from January 2019. The notice outlines how the Daily Volume-Weighted Average Price (VWAP) will be determined for these notes, detailing the use of specific time settings for trading observations. QIAGEN’s products span molecular diagnostics and life sciences, catering to over 500,000 customers globally.
Read more →QGENQIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening
QIAGEN announced the publication of a meta-analysis demonstrating the unique value of its QuantiFERON-TB Gold Plus test in tuberculosis screening. The study, which involved over 4,000 subjects, indicated a significantly higher interferon-gamma production in the test's TB2 tube, which detects CD8 T-cell responses, particularly in active TB disease cases. This advancement may enhance the ability to differentiate between active and latent TB infections, aiding in better patient risk stratification. The findings align with QIAGEN's ongoing commitment to improve diagnostic products for tuberculosis screening.
Read more →QGENQIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio
Venlo, the Netherlands, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the first quarter of 2023. Net sales for Q1 2023 declined 23% (-20% at constant exchange rates, CER) to $485 million from Q1 2022, which was marked b
Read more →QGENQIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk
Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberc
Read more →QGENQIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
Venlo, the Netherlands, April 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its QIAstat-Dx syndromic testing solution is expected to be available soon for use in Japan with a SARS-CoV-2 Respiratory Panel that can detect more
Read more →QGENQIAGEN announces expansion of Supervisory Board
Venlo, the Netherlands, April 20, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Steve Rusckowski, an internationally recognized healthcare industry executive and former Chairman, President and CEO of Quest Diagnostics, has joined
Read more →QGENQIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023
Venlo, the Netherlands, April 14, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biop
Read more →QGENQIAGEN’s QIAxcel Connect wins Red Dot design award
Venlo, the Netherlands, March 29, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced that QIAxcel Connect, its high-resolution gel electrophoresis instrument for use with DNA or RNA samples, has won the prestigious Red Dot award. This marks the fourth instrument from QIAGEN to recei
Read more →QGENQIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)
Venlo, The Netherlands, March 27, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based Targets initiative (SBTi) – a global recognition of its ambitions to ho
Read more →QGENNews Thermo Fisher Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail: karen.kirkwood@thermofisher.com Website: www.thermofisher.com Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-6
Thermo Fisher Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail: karen.kirkwood@thermofisher.com Website: www.thermofisher.com Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail: ken.apicerno@thermofisher.com QIAGEN Media Conta
Read more →QGENCONFIDENTIAL AND PRIVILEGED EXECUTION VERSION BUSINESS COMBINATION AGREEMENT between THERMO FISHER SCIENTIFIC INC. and QIAGEN N.V. Dated 3 March 2020 Contents Clause Page 1 DEFINITIONS AND CONSTRUCTION 9 1.1 Definitions
CONFIDENTIAL AND PRIVILEGED BUSINESS COMBINATION AGREEMENT THERMO FISHER SCIENTIFIC INC. Clause Page 1 DEFINITIONS AND CONSTRUCTION 9 1.1 Definitions 9 1.2 Construction 9 2 THE OFFER 10 2.1 Buyer Undertakings; Preparations of the Offer 10 2.2
Read more →QGENNews FOR IMMEDIATE RELEASE Thermo Fisher Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail: karen.kirkwood@thermofisher.com Website: www.thermofisher.com Thermo Fisher Investor Contact Information: Ken
FOR IMMEDIATE RELEASE Thermo Fisher Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail: karen.kirkwood@thermofisher.com Website: www.thermofisher.com Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail: ken.apicerno@thermof
Read more →QGENQIAGEN MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Qiagen N.V. is Fair to Shareholders; Investors are Encouraged to Contact the Firm – QGEN
NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of QIAGEN N.V. (NYSE: QGEN) to Thermo Fisher Scientific Inc. is fair to QIAGEN shareholders. On behalf of QIAGEN shareholders, Halper Sadeh LLP may
Read more →QGENQIAGEN and Tecan announce collaboration to streamline preanalytical processing of QuantiFERON-TB Gold Plus
Non-exclusive collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB detection Männedorf, Switzerland, and Germantown, Maryland, Hilden, Germany, March 8, 2019 – The Teca
Read more →QGENQIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018 HILDEN, Germany and GERMANTOWN, Md. and FORT MYERS, Fla., Nov. 30, 2018 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced
Read more →QGENQIAGEN and Clinical Genomics partner on liquid biopsies to monitor patients for recurrence of colorectal cancer
HILDEN, Germany and GERMANTOWN, Md. and BRIDGEWATER, N.J., Aug. 21, 2017 (GLOBE NEWSWIRE) -- QIAGEN (NASDAQ:QGEN) (Frankfurt Prime Standard:QIA) and Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced they have im
Read more →QGENQIAGEN Posts 2013 Annual Report on Its Website
VENLO, Netherlands, April 24, 2014 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2013 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports. QIAGEN's Annual Report on Form 20-F for the year
Read more →QGENQIAGEN N.V. to Report First Quarter 2014 Results and Hold Webcast
VENLO, Netherlands, April 9, 2014 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today reconfirmed plans to release its report on results for the first quarter 2014 on Tuesday, May 6, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also as previous
Read more →QGENQIAGEN N.V. to Report Fourth Quarter and Full-Year 2013 Results and Hold Webcast
VENLO, The Netherlands, Jan. 13, 2014 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today reconfirmed plans to release its report on results for the fourth quarter and full-year of 2013 on Wednesday, January 29, at 22:00 Central European Time (CET) / 16:00 Eastern
Read more →QGENQIAGEN announces European launch of therascreen(r) IDH1/2 test for gliomas
QIAGEN announces European launch of therascreen IDH1/2 test for gliomas as well as a IDH1/2-related collaboration with Mayo Clinic QIAGEN's therascreen IDH1/2 RGQ Kit is the first CE-marked test targeting IDH1 and IDH2 biomarkers to diagnose brain gliomas and assess prognoses P
Read more →QGENQIAGEN N.V. to Announce Third Quarter 2013 Financial Results
VENLO, The Netherlands, Oct. 9, 2013 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today reconfirmed plans to release its report on results for the third quarter of 2013 on Tuesday, October 29, at 21:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also
Read more →QGENQIAGEN N.V. to Announce Second Quarter 2013 Financial Results
VENLO, The Netherlands, July 16, 2013 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today reconfirmed plans to release its report on results for the second quarter of 2013 on Tuesday, July 30, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also a
Read more →QGENQIAGEN Posts 2012 Annual Report on Its Website
VENLO, Netherlands, May 15, 2013 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2012 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports. QIAGEN's Annual Report on Form 20-F for the year e
Read more →QGENQIAGEN N.V. to Report First Quarter 2013 Results and Hold Webcast
VENLO, The Netherlands, April 15, 2013 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) today reconfirmed plans to release its report on results for the first quarter of 2013 on Monday, April 29, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also as previously ann
Read more →QGENQIAGEN N.V. to Report Fourth Quarter and Full-Year 2012 Results and Hold Webcast
VENLO, The Netherlands, Jan. 15, 2013 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today reconfirmed plans to release its report on results for the fourth quarter and full-year 2012 on Tuesday, January 29, at 22:00 Central European Time (CET) / 16:00 Eastern Time
Read more →QGENQIAGEN to Present at the 31st Annual J.P. Morgan Healthcare Conference
VENLO, The Netherlands, Jan. 4, 2013 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) announced today that it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California. QIAGEN's presentation will take place on Monday, January 7, 2
Read more →QGENQIAGEN N.V. Reschedules Publication of Q3 2012 Results Due to Severe U.S. Weather Conditions
VENLO, The Netherlands, Oct. 30, 2012 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) announces today that it has decided to postpone the issuance of its report for third quarter and first nine months of 2012 due to the severe weather conditions in the United States
Read more →QGENQIAGEN N.V. to Report Third Quarter 2012 Results and Hold Webcast
VENLO, Netherlands, Oct. 16, 2012 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) today reconfirmed plans to release its report on results for the third quarter of 2012 on Monday, October 29, at 21:00 Central European Time (CET) / 16:00 Eastern Time (ET). A webcast is planned for
Read more →QGENQIAGEN N.V. to Report Second Quarter 2012 Results and Hold Webcast
VENLO, Netherlands, July 23, 2012 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) today reconfirmed plans to release its report on results for the second quarter of 2012 on Tuesday, July 24, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also as previously announc
Read more →QGENQIAGEN Posts 2011 Annual Report on Its Website
VENLO, Netherlands, May 8, 2012 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2011 Annual Report on its website at http://www.qiagen.com/about/investorrelation/aboupdf/qia_ar11_web.pdf. QIAGEN's Annual Report on Form 20-F for the year ended Decembe
Read more →QGENTable of Contents
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of For the quarterly period ended March 31, 2012 Commission File Number 0-28564 (Translation of
Read more →QGENQIAGEN N.V. to Report First Quarter 2012 Results and Hold Webcast
VENLO, Netherlands, April 18, 2012 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) today reconfirmed plans to release its report on results for the first quarter of 2012 on Wednesday, April 25, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also as previously anno
Read more →QGENQIAGEN Posts 2010 Annual Report on Its Website
VENLO, Netherlands, May 16, 2011 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2010 Annual Report on its website at http://www.qiagen.com/about/investorrelation/aboupdf/110509_qia_ar10_web.pdf">http://www.qiagen.com/about/investorrelation/aboupdf/11
Read more →QGENQIAGEN Reports First Quarter 2011 Results
Net sales of $264.3 million (0%, -2% CER) reflect anticipated soft start to 2011, disruptions in Japan and other markets reduce growth by ~2 percentage points Adjusted EPS rises to $0.21 (+5%) on productivity initiatives that support investments to drive innovation and growth; f
Read more →QGENQIAGEN Reports Full-Year and Fourth Quarter 2010 Results
Full-year net sales of $1.09 billion achieve target, with +8% CER organic growth excluding swine flu-related products Full-year adjusted EPS of $0.93 ($0.94 CER) achieves target as productivity initiatives underpin adjusted operating income margin of 28% (29% CER) Strategic ini
Read more →QGENQIAGEN to Present at the JPMorgan 29th Annual Healthcare Conference
VENLO, Netherlands, Jan. 4, 2011 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the JPMorgan 29th Annual Healthcare Conference at 2:30 p.m. PT on Tuesday, January 11, 2011. The conference is being held at Westin St. Francis i
Read more →QGENQIAGEN Reports Third Quarter 2010 Results
Net sales of $274.3 million in line with QIAGEN's quarterly expectations, 8% organic net sales growth excluding swine flu-related products Adjusted EPS of $0.25 ($0.27 CER) exceeds target, adjusted operating income margin exceeds 29% of net sales (30% CER) QIAsymphony RGQ launc
Read more →QGENQIAGEN Reports Solid Second Quarter 2010 Results
11% Revenue growth at constant exchange rates 10% Organic growth excluding H1N1 related effects 25% Net income growth VENLO, Netherlands, Aug. 9, 2010 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for the second quarter
Read more →QGENQIAGEN Posts 2009 Annual Report on Its Website
VENLO, Netherlands, June 1, 2010 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2009 Annual Report on its website at http://www.qiagen.com/about/investorrelation/financialinformation/financialreports.aspx. QIAGEN's Annual Report on Form 20-F for the
Read more →QGENQIAGEN Reports Strong First Quarter 2010 Results
22% Net income growth (adj.) VENLO, Netherlands, May 3, 2010 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the
Read more →QGENQIAGEN Reports Strong Fourth Quarter and Fiscal 2009 Results
VENLO, Netherlands, Feb. 8, 2010 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for the fourth quarter and the fiscal year ended December 31, 2009. The reported net sales for the fourth quarter 2009 exceeded the guidance a
Read more →QGENQIAGEN to Present at the JPMorgan 28th Annual Healthcare Conference
VENLO, Netherlands, Jan. 6, 2010 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the JPMorgan 28th Annual Healthcare Conference at 11:30 a.m. PT on Wednesday, January 13, 2010. The conference is being held at Westin St. Franci
Read more →QGENQIAGEN Added to NASDAQ-100 Index
VENLO, The Netherlands, Dec. 14, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that its common shares will be included in the NASDAQ-100 Index effective as of the start of trading on December 21, 2009. The NASDAQ-100 Index comprises the top 10
Read more →QGENQIAGEN Reports Strong Third Quarter 2009 Results
* 16% Revenue Growth on Constant Exchange Rates * 15% Organic Revenue Growth * 31% Operating Margin, adjusted * $0.26 Adjusted EPS VENLO, The Netherlands, Nov. 9, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for
Read more →QGENQIAGEN Announces Exercise in Full of Over-Allotment Option by Underwriters in Offering of New Common Shares
VENLO, The Netherlands, Sept. 29, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) (the "Company") announces that the underwriters for its offering of 27.5 million newly issued common shares (the "Offering") have exercised in full their over-allotment option to
Read more →QGENQIAGEN Announces Pricing of Offering of New Common Shares
VENLO, the Netherlands, Sept. 24, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) (the "Company") announces that it will issue 27.5 million newly issued common shares (the "Shares") in connection with the offering announced on September 22, 2009 (the "Offering"
Read more →QGENQIAGEN Announces An Offering of New Common Shares
VENLO, The Netherlands, Sept. 22, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) (the "Company") announces today the launch of a placement of up to 27.5 million newly issued common shares through a bookbuilding process (the "Offering"). In addition, the Compan
Read more →QGENQIAGEN Acquires DxS Ltd -- Creating Leadership in Personalized Healthcare
VENLO, The Netherlands, Sept. 22, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it has acquired DxS Ltd (DxS), a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, United Kingdom. The t
Read more →QGENQIAGEN Reports Strong Second Quarter 2009 Results and Increases Full Year 2009 Guidance
* 19% Revenue Growth on Constant Exchange Rates * 12% Organic Growth * $0.24 Adjusted EPS, exceeds guidance VENLO, The Netherlands, Aug. 10, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for the second quarter and
Read more →QGENQIAGEN Transfers Distribution Rights for Transplantation Testing Product Portfolio and Related Assets to LinkMed
VENLO, The Netherlands, June 16, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it has signed an agreement to transfer distribution rights on July 1, 2009 for the Olerup SSP(r) product line and the related assets to Olerup International AB
Read more →QGENQIAGEN to Present At the Goldman Sachs 30th Annual Global Healthcare Conference
VENLO, Netherlands, June 3, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the Goldman Sachs 30th Annual Global Healthcare Conference at 3:50 p.m. ET on Wednesday, June 10, 2009. The conference is being held at Grand Hya
Read more →QGENQIAGEN Posts 2008 Annual Report On Its Website
VENLO, The Netherlands, June 3, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2008 Annual Report on its website at www.qiagen.com/agm2009. QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2008 has been filed with the U.S. Sec
Read more →QGENQIAGEN to Present At the Bank of America and Merrill Lynch 2009 Healthcare Conference
VENLO, The Netherlands, May 7, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the Bank of America and Merrill Lynch 2009 Healthcare Conference at 10:00 a.m. ET on Wednesday, May 13, 2009. The conference is being held at
Read more →QGENQIAGEN to Present At Baird's 2009 Growth Stock Conference
VENLO, The Netherlands, May 6, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at Baird's 2009 Growth Stock Conference at 1:55 p.m. CDT on Wednesday, May 12, 2009. The conference is being held at the Four Seasons Hotel in Ch
Read more →QGENQIAGEN Reports First Quarter 2009 Results
* 16% Revenue Growth On Constant Exchange Rates * 11% Organic Growth * $0.20 Adjusted EPS VENLO, The Netherlands, May 4, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for its first quarter ended March 31, 2009. Re
Read more →QGENQIAGEN Reports Strong Fourth Quarter and Fiscal 2008 Results
* 35% Constant Currency and 13% Organic Revenue Growth in 2008 * 54% Growth in Adjusted Operating Income in 2008 * 47% Growth in Adjusted Net Income in 2008 VENLO, The Netherlands, Feb. 9, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced preli
Read more →QGENQIAGEN and Applied Biosystems Settle All Disputes Over Real-Time PCR Thermal Cycler Patents
VENLO, The Netherlands, Jan. 22, 2009 (GLOBE NEWSWIRE) -- Corbett, QIAGEN (Nasdaq:QGEN) (Frankfurt:QIA), ltf Labortechnik GmbH & Co. KG, and Applied Biosystems, LLC, part of Life Technologies Corporation (Nasdaq:LIFE) today announced a settlement of their disputes concerning infr
Read more →QGENQIAGEN to Present At the JPMorgan 27th Annual Healthcare Conference
VENLO, The Netherlands, Jan. 7, 2009 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the JPMorgan 27th Annual Healthcare Conference at 11:30 a.m. PT on Wednesday, January 14, 2009. The conference is being held at Westin St. Fr
Read more →QGENQIAGEN Introduces CE-marked Molecular Assay for the Cancer Biomarker K-ras
VENLO, The Netherlands, Nov. 10, 2008 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the launch of a new test to determine mutations of the K-ras gene. The K-ras gene is mutated in between 35 percent and 45 percent of metastatic colorectal cancer (C
Read more →QGENQIAGEN Reports Strong Third Quarter 2008 Results
* 31% Revenue Growth, 14% Organic Growth * 53% Adjusted Operating Income Growth * $0.21 Adjusted EPS VENLO, The Netherlands, Nov. 10, 2008 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for the third quarter and the nine
Read more →QGENQIAGEN Acquires Biosystems Business From Biotage
VENLO, The Netherlands, Oct. 1, 2008 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it has acquired all assets related to the Biosystems business from Biotage AB, a publicly listed developer, manufacturer and distributor of products for genetic
Read more →QGENQIAGEN to Present At the 2008 UBS Global Life Sciences Conference
VENLO, The Netherlands, Sept. 18, 2008 (GLOBE NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the 2008 UBS Global Life Sciences Conference at 12:00 p.m. ET on Monday, September 22, 2008. The conference is being held at The Grand Hyat
Read more →QGENQiagen launches Olerup SSP AB's new test for detecting adverse reactions to HIV-medicine in the EU
Qiagen launches Olerup SSP AB's new test for detecting adverse reactions to HIV-medicine in the EU LinkMed's wholly owned subsidiary Olerup SSP AB has developed a new test that detects genetic variations in the Human Leucocyte Antigen (HLA) system that indicate risk for sever
Read more →QGENQIAGEN and Idaho Technology Settle Patent Dispute
VENLO, The Netherlands and SALT LAKE CITY, Aug. 4, 2008 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) and Idaho Technology, Inc. are pleased to announce that the companies have reached a settlement agreement for rights to a suite of intellectual property relating
Read more →QGENQIAGEN Reports Second Quarter 2008 Results and Increases Full Year 2008 Adjusted EPS Guidance
* 61% Revenue Growth, 11% Organic Growth * 68% Adjusted Operating Income Growth * $0.20 Adjusted EPS VENLO, The Netherlands, Aug. 4, 2008 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt, Prime Standard:QIA) today announced the results of operations for the second quar
Read more →QGENQIAGEN Acquires Corbett Life Science
VENLO, The Netherlands, July 1, 2008 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it has acquired Corbett Life Science Pty. Ltd. (Corbett), a privately-held developer, manufacturer, and distributor of life sciences instrumentation headquarter
Read more →QGENQIAGEN Files Appeal in Patent Case
GAITHERSBURG, Md., June 11, 2008 (PRIME NEWSWIRE) -- QIAGEN Gaithersburg, Inc. (formerly Digene Corporation), a wholly-owned subsidiary of QIAGEN N.V. (NASDAQ:QGEN) (Frankfurt:QIA), today announced that it has filed its initial brief with the United States Court of Appeals for th
Read more →QGENQIAGEN to Present At the Goldman Sachs 29th Annual Global Healthcare Conference
VENLO, The Netherlands, June 6, 2008 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the Goldman Sachs 29th Annual Global Healthcare Conference at 3:20 p.m. PT on Tuesday, June 10, 2008. The conference is being held at The Rit
Read more →QGENQIAGEN to Present At Bank of America 2008 Health Care Conference
VENLO, The Netherlands, May 8, 2008 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at Bank of America 2008 Health Care Conference at 2:00 p.m. ET on Wednesday, May 14, 2008. The conference is being held at the Four Seasons Hotel
Read more →QGENQIAGEN to Present At Baird's 2008 Growth Stock Conference
VENLO, The Netherlands, May 7, 2008 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at Baird's 2008 Growth Stock Conference at 10:05 a.m. ET on Tuesday, May 13, 2008. The conference is being held at the Four Seasons Hotel in Chic
Read more →QGENQIAGEN Reports Strong First Quarter 2008 Results
* 62% Revenue Growth, 10% Organic Growth * 79% Adjusted Operating Income Growth * $0.18 Adjusted EPS VENLO, The Netherlands, May 5, 2008 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for its first quarter ended on March
Read more →QGENQIAGEN and BioHelix Enter Into Licensing Agreement
VENLO, The Netherlands and BEVERLY, Mass., April 30, 2008 (PRIME NEWSWIRE) -- QIAGEN (Nasdaq:QGEN) (Frankfurt:QIA) and privately held BioHelix have announced today that they have entered into a non-exclusive worldwide license and supply agreement for BioHelix's proprietary Helica
Read more →QGENQIAGEN to Present At Deutsche Bank 33rd Annual Health Care Conference
VENLO, The Netherlands, April 29, 2008 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN), (Frankfurt:QIA) today announced that it will present at the Deutsche Bank 33rd Annual Health Care Conference at 2:10 p.m. EDT on Tuesday, May 06, 2008. The conference is being held at the InterC
Read more →QGENQIAGEN Reports Strong Fourth Quarter and Fiscal 2007 Results
* 34% Constant Currency and 12% Organic Revenue Growth in 2007 * 31% Growth in Adjusted Net Income in 2007 * Fourth Quarter 2007 Adjusted EPS Exceeds Guidance by $0.02 * Guidance 2008: Revenues $875 to $905 million (growth rate 35% to 40%) Adj. EPS $0.76 to $0.80 VENLO, The
Read more →QGENQIAGEN Wins Judgment Against Third Wave
GAITHERSBURG, Md., Jan. 11, 2008 (PRIME NEWSWIRE) -- QIAGEN Gaithersburg Inc. (formerly Digene Corporation), a wholly owned subsidiary of QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it was granted summary judgment on the antitrust counterclaims asserted against
Read more →QGENQIAGEN to Supply Singapore Ministry of Health With Avian Flu Surveillance Solutions
VENLO, The Netherlands, Jan. 8, 2008 (PRIME NEWSWIRE) -- QIAGEN (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it has been awarded an exclusive contract by the Singapore Ministry of Health to supply sample preparation solutions and molecular tests for the specific detection o
Read more →QGENQIAGEN and Ventana Announce Settlement of Patent Dispute
GAITHERSBURG, Md. and TUCSON, Ariz., Dec. 19, 2007 (PRIME NEWSWIRE) -- QIAGEN Gaithersburg Inc. (formerly Digene Corporation), a wholly owned subsidiary of QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) ("QIAGEN" or the "Company"), and Ventana Medical Systems, Inc. (Nasdaq:VMSI) today
Read more →QGENQIAGEN to Present At the JPMorgan 26th Annual Healthcare Conference
VENLO, The Netherlands, Dec. 12, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the JPMorgan 26th Annual Healthcare Conference at 10:30 a.m. PT on Tuesday, January 8, 2008. The conference is being held at Westin St. Fran
Read more →QGENQIAGEN Reports Third Quarter 2007 Results Increases Full Year 2007 Guidance
* 50% Revenue Growth * $0.17 Adjusted Diluted EPS * 43% Adjusted Operating Income Growth * Increasing Full Year 2007 Adjusted EPS Guidance by $0.03 to $0.61-$0.62 VENLO, Netherlands, Nov. 5, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced t
Read more →QGENQIAGEN to Present At the 2007 UBS Global Life Sciences Conference
VENLO, The Netherlands, Sept. 17, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced that it will present at the 2007 UBS Global Life Sciences Conference at 10:30 a.m. EDT on Monday, September 24, 2007. The conference is being held at The Grand Hya
Read more →QGENQIAGEN Reports Strong Second Quarter 2007 Results
* 19% Revenue Growth, 15% Constant Currency and 11% Organic Growth * 30% Adjusted Net Income Growth * $0.16 Adjusted EPS VENLO, The Netherlands, Aug. 6, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for the quarter
Read more →QGENInformation: QIAGEN Investors: Dr. Solveigh M hler 011-49-2103-29-11710 Media: Dr. Thomas Theuringer 011-49-2103-29-11826 QIAGEN ANNOUNCES COMPLETION OF DIGENE ACQUISITION Venlo, The Netherl
Contact Information: QIAGEN ANNOUNCES COMPLETION OF DIGENE ACQUISITION Venlo, The Netherlands July 30, 2007 QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) announced today the successful completion of its acquisition of Digene Corporation (Nasdaq: DIGE). QIAGEN comp
Read more →QGENInformation: QIAGEN Investors: Dr. Solveigh M hler Inside the US: (240) 686 2222 International: +49 2103 29 11710 Media: Dr. Thomas Theuringer +49 2103 29 11826 QIAGEN EXCHANGE OFFER FOR DIG
QIAGEN EXCHANGE OFFER FOR DIGENE CORPORATION EXPIRED WITH SIGNIFICANTLY OVER 90% OF SHARES TENDERED The Netherlands July 23, 2007 QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced that its offer to exchange cash and stock for all outstanding shares of D
Read more →QGENQIAGEN Completes Acquisition of eGene
VENLO, The Netherlands, July 9, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN); (Frankfurt: QIA), the world's leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics, today announced that its subsidiary QIAGEN
Read more →QGENQIAGEN Launches First QIAplex Products for Highly Multiplexed, PCR-Based Assays
VENLO, The Netherlands, June 1, 2007 (PRIME NEWSWIRE) -- QIAGEN (Nasdaq:QGEN) (Frankfurt:QIA), the world's leading provider of sample and assay technologies for research in life sciences, applied testing, and molecular diagnostics, today announced the launch of the first assays b
Read more →QGENQIAGEN and Biomatrica Announce Strategic Partnership Targeting Biological Sample Storage and Management Systems
VENLO, The Netherlands, May 31, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA), the worldwide leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics today announced that it has entered into a
Read more →QGENQIAGEN and Epigenomics Expand Successful Partnership
BERLIN and VENLO, The Netherlands, May 29, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) (Prime Standard:QIA) and Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX) today announced that the companies further expanded their existing strategic partnership by a
Read more →QGENQIAGEN Launches Novel Assay Technology for miRNA Targets
VENLO, The Netherlands, May 7, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA), the world's leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics, today introduced a pioneering technology whic
Read more →QGENQIAGEN Reports Strong First Quarter 2007 Results
* 18% Revenue Growth, 13% Constant Currency and 11% Organic Growth * 17% Adjusted Net Income Growth * $0.14 Adjusted EPS VENLO, The Netherlands, May 7, 2007 (PRIME NEWSWIRE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today announced the results of operations for its first qu
Read more →QGENQIAGEN's Molecular Assays Detect Recently Discovered Chlamydia Trachomatis Strain
VENLO, Netherlands, Feb. 28, 2007 (PRIME NEWSWIRE) -- QIAGEN, the world's leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics, today announced, that the County Hospital in Halmstad, Sweden, confirmed reliable
Read more →QGENQIAGEN Introduces Novel Technology and Product Line That Significantly Accelerates PCR Reactions
VENLO, Netherlands, Oct. 24, 2006 (PRIMEZONE) -- QIAGEN, the world's leading provider of products for preanalytical sample preparation and molecular diagnostics, today launched its new QIAGEN Fast Cycling PCR product line, which substantially accelerates and streamlines the polym
Read more →QGENQIAGEN N.V. (QGEN) CEO to Ring the NASDAQ Stock Market Opening Bell
MEDIA ADVISORY, June 28, 2006 (PRIMEZONE) -- Mr. Peer Schatz, CEO of QIAGEN N.V. (QGEN) will preside over the opening bell to celebrate its 10 year listing anniversary on the NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Thursday June 29th, 2006 at 9:30 a.m
Read more →QGENQIAGEN to Present at the UBS Global Life Sciences Conference
VENLO, Netherlands, Sept. 19, 2005 (PRIMEZONE) -- QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt, Prime Standard: QIA) today announced that it will present at the UBS Global Life Sciences Conference at 1:00 p.m. EDT on Monday, September 26, 2005. The conference is being held at The Grand H
Read more →QGENQIAGEN and Evotec Technologies Demonstrate Significant Benefits of Combining RNAi Applications with High-Content Cellular Imaging Systems
VENLO, The Netherlands and HAMBURG, Germany, Sept. 13, 2004 (PRIMEZONE) -- QIAGEN N.V. (Nasdaq:QGENF) (Deutsche Borse: QIA, Prime Standard) and Evotec Technologies GmbH today announced that they have signed an agreement to promote the benefits of combining QIAGEN's proprietary TO
Read more →QGENPeer M. Schatz Chief Executive Officer QIAGEN N.V. +49 2103 29 11702 e-mail: peer.schatz@QIAGEN.com Dr. Solveigh M hler Investor Relations QIAGEN N.V. +49 2103 29 11710 e-mail: solveigh.maehler@QIAGEN.com QIAGE
Offering of Convertible Notes Venlo, The Netherlands, August 4, 2004 - QIAGEN N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA) ( QIAGEN or the Company ) today announced that it plans to offer US$150 million of senior unsubordinated convertible notes (the Notes ) due 2024 t
Read more →QGENQIAGEN Announces Closure of Bothell/Seattle Facility Decision Expected to Increase QIAGEN s Future Profitability Bothell, Washington and Venlo, Netherlands
QIAGEN Announces Closure of Bothell/Seattle Facility Decision Expected to Increase QIAGEN s Future Profitability Bothell, Washington and Venlo, Netherlands, January 08, 2003 QIAGEN N.V. (Nasdaq: QGENF, Frankfurt, Neuer Markt: QIA) today announced plans to close its Bothell, W
Read more →QGENQIAGEN to Present at the 4th Annual UBS Warburg Global Life Sciences Conference Venlo, The Netherlands
QIAGEN to Present at the 4th Annual UBS Warburg Global Life Sciences Conference Venlo, The Netherlands, October 02, 2002 - QIAGEN N.V. (NASDAQ: QGENF, Neuer Markt: QIA) today announced that it will present at the 4th Annual UBS Warburg Global Life Sciences Conference at 9:00 a
Read more →QGENQIAGEN and Affymetrix enter into Supply Agreement for Nucleic Acid Purification Solutions for GeneChip? Arrays Venlo, The Netherlands
PRESS RELEASE DATED JUNE 10, 2002 QIAGEN and Affymetrix enter into Supply Agreement for Nucleic Acid Purification Solutions for GeneChip? Arrays Venlo, The Netherlands, June 10, 2002 - QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA) and Affymetrix, Inc. (NASDAQ: AFFX) today ann
Read more →QGENQIAGEN Provides Update on Business Outlook Venlo, The Netherlands
QIAGEN Provides Update on Business Outlook Venlo, The Netherlands, July 3, 2002 - QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA) today announced an update of the Company's forecasts for its financial performance in 2002 and 2003. On a world-wide basis, QIAGEN's customers can b
Read more →QGENdex99.txt PRESS RELEASE [QIAGEN LOGO] Contacts: Peer M. Schatz Noonan Russo Presence Chief Financial Officer Veronica Sellar QIAGEN N.V. +44 (0)20 7726 4452 +49 2103 2911 702 Mary Claire Duch e-mail: p.schatz@de.QIAGEN.c
Peer M. Schatz Noonan Russo Presence Chief Financial Officer Veronica Sellar QIAGEN N.V. +44 (0)20 7726 4452 +49 2103 2911 702 Mary Claire Duch e-mail: p.schatz@de.QIAGEN.com +1 212 845 4278 ---------------------- Manager Investor Relations e-mail: s.maehler@de.QIAGEN.com
Read more →QGENQIAGEN Opens North American Headquarters in Montgomery County, Maryland Venlo, The Netherlands
PRESS RELEASE DATED JANUARY 11, 2002 QIAGEN Opens North American Headquarters in Montgomery County, Maryland Venlo, The Netherlands, January 11, 2002 - QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA; Easdaq: QGEN) announced today the opening of its new, state-of-the-art researc
Read more →Competitive Position
How QGEN ranks across every disease it competes inCompetitive Position is a premium feature
See how QGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial